Humana Inc. (NYSE:HUM) Shares Bought by Virtu Financial LLC

Virtu Financial LLC boosted its holdings in shares of Humana Inc. (NYSE:HUM) by 56.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,123 shares of the insurance provider’s stock after purchasing an additional 1,490 shares during the period. Virtu Financial LLC’s holdings in Humana were worth $1,429,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. purchased a new stake in shares of Humana during the fourth quarter worth about $25,000. Cetera Trust Company N.A purchased a new stake in Humana during the 4th quarter valued at about $28,000. Private Wealth Management Group LLC purchased a new stake in Humana during the 4th quarter valued at about $32,000. Carolinas Wealth Consulting LLC grew its stake in Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after acquiring an additional 74 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in Humana during the 4th quarter valued at about $55,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Performance

Humana stock traded up $4.64 during trading hours on Friday, reaching $363.62. 1,021,130 shares of the company were exchanged, compared to its average volume of 1,748,450. The stock has a 50-day moving average of $367.62 and a 200 day moving average of $347.54. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54. The firm has a market cap of $43.82 billion, a price-to-earnings ratio of 22.33, a PEG ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.17% and a net margin of 1.53%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business posted $8.94 earnings per share. As a group, research analysts anticipate that Humana Inc. will post 16.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HUM. Robert W. Baird started coverage on shares of Humana in a research note on Thursday, May 30th. They set a “neutral” rating and a $374.00 price objective for the company. Truist Financial boosted their target price on shares of Humana from $355.00 to $400.00 and gave the company a “hold” rating in a report on Monday, July 15th. UBS Group decreased their target price on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, April 25th. Piper Sandler started coverage on shares of Humana in a report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 target price on the stock. Finally, Wells Fargo & Company decreased their price objective on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a report on Monday, April 8th. Fourteen analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Humana presently has an average rating of “Hold” and a consensus price target of $403.55.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.